Drug Trial Radar · NCT01397097
LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study
Last checked: Nov 20, 2026Latest source record: Jul 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
766
Actual
Start
Sep 2011
Primary completion
Jun 2013
Study completion Apr 2015
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jul 19, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to demonstrate that discontinuation rates in women (ages 18-35 years inclusive) using LCS12 are not higher than those seen in women using ENG subdermal implant over a period of 12 months. Secondary objectives are to observe the bleeding patterns, adverse event profiles and the occurrence of unintended pregnancies. Additionally, data on user satisfaction, IUS expulsions and implant site complications will be collected.
Conditions
- Contraception
Interventions
LNG-IUS (BAY 86-5028)Drug
LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years
68 mg etonorgestrel implant for subdermal use (Nexplanon)Drug
Implant insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months, may be continued up to 3 years under standard care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Discontinuation rate by treatment groupTime frame: at 12 months
Locations
43 sites in 6 countries. Site status is shown where the registry gives one.
Site not named
Ashfield, New South Wales, Australia
Site not named
Sydney, New South Wales, Australia
Site not named
North Adelaide, South Australia, Australia
Site not named
Parkville, Victoria, Australia
Site not named
Nedlands, Western Australia, Australia
Site not named
Espoo, Finland
Site not named
Helsinki, Finland
Site not named
Helsinki, Finland
Site not named
Helsinki, Finland
Site not named
Kuopio, Finland
Site not named
Tampere, Finland
Site not named
Tampereen Yliopisto, Finland
Site not named
Turku, Finland
Site not named
Turku, Finland
Site not named
Biarritz, France
Site not named
Bordeaux, France
Site not named
Marseille, France
Site not named
Quetigny, France
Site not named
Reims, France
Site not named
Schiltigheim, France
Site not named
Seclin, France
Site not named
Strasbourg, France
Site not named
Elverum, Norway
Site not named
Haugesund, Norway
Site not named
Ski, Norway
Site not named
Straume, Norway
Site not named
Trondheim, Norway
Site not named
Gothenburg, Sweden
Site not named
Gothenburg, Sweden
Site not named
Linköping, Sweden
Site not named
Luleå, Sweden
Site not named
Malmö, Sweden
Site not named
Malmö, Sweden
Site not named
Örebro, Sweden
Site not named
Stockholm, Sweden
Site not named
Stockholm, Sweden
Site not named
Uppsala, Sweden
Site not named
Liverpool, United Kingdom
Site not named
London, United Kingdom
Site not named
Cambridge, Cambridgeshire, United Kingdom
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.